Mr. Saxe has served as a director of over 25 companies and at present is a director of three public companies, Durect Corporation (NASDAQ: DRRX), VistaGen (NASDAQ:VTGN) and SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) and private companies Arbor Vita, Arcuo Medical, Armetheon, Cancer Prevention Pharmaceuticals, Lumos Pharma and Trellis Bioscience.
Mr. Saxe is Chairman of SciClone, Vista Gen and Vytacera. He was President of PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) (NASDAQ: PDLI) from 1995 to 1999. In 1999-2000 he was E-I-R at Institutional Venture Partners. From 1993 to 1995, Mr. Saxe was Principal of Saxe Associates, Inc., consultants to venture capital firms and biotechnology, diagnostic and pharmaceutical companies.
From 1989 to 1993 he was the President and CEO of Synergen, Inc., a biotechnology company purchased by Amgen. Prior to then Mr. Saxe was Vice President, Licensing and Corporate Development and Head of Patent Law for Hoffmann-LaRoche Inc., where he worked for 29 years. Mr. Saxe received a B.S.Ch,E. from Carnegie Mellon University, his J.D. from George Washington University School of Law, his LL.M. from New York University School of Law and a Certificate in Business Administration from Duke University.